Factor Vii Deficiency

• CLINICAL_TRIALS trial_result · 2026-03-10
  Clinical Trial Update: A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) [Phase 1]

  Phase 1 clinical trial evaluating SR604 for safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and in pati…

• CLINICAL_TRIALS research · 2026-01-30
  Clinical Trial Update: A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency [Phase 2]

  A Phase 2 clinical study is assessing Sutacimig in participants with congenital Factor VII deficiency and is currently recruiting.

• CLINICAL_TRIALS research · 2025-08-08
  Clinical Trial Update: Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage.

  This clinical trial compares the performance of different thromboplastin reagents on prothrombin time and factorial assays in individuals wi…

• EMA approval · 2023-02-27
  EMA Authorised: NovoSeven (eptacog alfa (activated)) — Novo Nordisk A/S

  The EMA authorised NovoSeven (eptacog alfa activated) from Novo Nordisk A/S for multiple indications including Hemophilia A/B, Factor VII de…

• EMA withdrawal · 2022-09-27
  EMA Application withdrawn: HemAryo (eptacog alfa (activated)) — UGA Biopharma

  EMA withdrawn the application for HemAryo (eptacog alfa activated) by UGA Biopharma for hemophilia A, hemophilia B, and factor VII deficienc…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2021-02-04
  Clinical Trial Update: Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency [Phase 3]

  A Phase 3 trial comparing pharmacokinetics of a biosimilar Eptacog Alfa with NovoSeven in patients with congenital Factor VII deficiency has…

• CLINICAL_TRIALS trial_result · 2014-10-20
  Clinical Trial Update: Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

  This completed observational study evaluates the safety and efficacy of NovoSeven (recombinant activated factor VII) in individuals with con…

• CLINICAL_TRIALS trial_result · 2012-11-27
  Clinical Trial Update: Treatment of Inherited Factor VII Deficiency

  This update notes that a clinical trial studying treatment for inherited Factor VII deficiency has completed.